MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

We recently compiled a list of the These 10 Companies Led Gains on Wednesday. In this article, we are going to take a look at ...

The Trump administration has placed a pause on all external health communications from federal health agencies, including the ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20 ...

According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of ...

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.

TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS) is awarding the ...

The Department of Health Services has awarded $590 million to Moderna to speed up the development of flu vaccines, including ...

Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The ...

In some good news for the US vaccines developer, whose stock has fallen 66% in the past 12 months, Moderna on Friday ...

Georgia has suspended all poultry activities after bird flu was confirmed during a commercial poultry operation. The positive ...